gallium ga 68 satoreotide trizoxetan

Gallium Ga 68 satoreotide trizoxetan (also known as 68Ga-OPS202, 68Ga-NODAGA-JR11, or 68Ga-SSO120) is an investigational radiolabeled somatostatin receptor subtype 2 (SSTR2) antagonist developed as a diagnostic imaging agent for positron emission tomography (PET/CT). It consists of the somatostatin antagonistic peptide JR11 conjugated to the cyclical chelating agent NODAGA and radiolabeled with the positron-emitting radionuclide gallium-68 (68Ga). Unlike conventional SSTR agonists (such as 68Ga-DOTATATE or 68Ga-DOTATOC) which internalize into cells, satoreotide trizoxetan binds to both active and inactive states of SSTR2 on the cell membrane without triggering internalization, allowing it to recognize a higher number of receptor binding sites. This results in superior tumor-to-background ratios and enhanced detection of SSTR2-positive lesions, particularly liver metastases. Originally developed by OctreoPharm Sciences and subsequently by Ipsen, the rights to satoreotide trizoxetan were acquired in 2021 by Ariceum Therapeutics, which is developing it as a companion diagnostic/theranostic pair alongside therapeutic SSTR2 antagonists like lutetium Lu 177 satoreotide tetraxetan or actinium Ac 225 satoreotide.

Other names

68Ga-satoreotide68Ga-satoreotide trizoxetanGa-68-NODAGA-JR11Ga68-NODAGA-JR11Ga 68-NODAGA-JR11Ga-68-OPS202Ga68-OPS202Ga 68-OPS202Ga-68-satoreotide trizoxetanGa68-satoreotide trizoxetanGa 68-satoreotide trizoxetangallium (68Ga) satoreotide trizoxetangallium Ga-68 satoreotide trizoxetangallium-68 satoreotidegallium68 satoreotidegallium 68 satoreotidegallium-68 satoreotide trizoxetangallium68 satoreotide trizoxetangallium 68 satoreotide trizoxetanNODAGA-JR11NODAGA-JR-11NODAGA-JR 11satoreotide trizoxetan